Pennsylvania 2025_0 Regular Session Status: In Committee Bipartisan · 15 D · 4 R cosponsors

HB 1439 — An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control.

Last action — Referred to HEALTH, May 12, 2025

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced May 12, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 42% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 19 sponsors

    1 primary, 18 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (15 D · 4 R) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Legislation to Expedite Access to FDA-Approved Psilocybin Treatments

Bill Text

Action History

  1. Referred to HEALTH, May 12, 2025

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 18 co-sponsors · 234 not signed on

Sponsors (1)

Co-sponsors (18)

Not signed on (234)

234 members have not signed on to this bill.

Show all 234 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 1439 do?
Legislation to Expedite Access to FDA-Approved Psilocybin Treatments
Who sponsors HB 1439?
HB 1439 is sponsored by Craig Williams (Republican), Jennifer O'Mara (Democratic), Maureen E. Madden (Democratic), Christopher M. Rabb (Democratic), Tarik Khan (Democratic), Benjamin V. Sanchez (Democratic), Mandy Steele (Democratic), Joseph C. Hohenstein (Democratic), Carol Hill-Evans (Democratic), Melissa Cerrato (Democratic), Nikki Rivera (Democratic), Mark M. Gillen (Republican), Lisa A. Borowski (Democratic), Jose Giral (Democratic), Michael Stender (Republican), Paul Takac (Democratic), R. Lee James (Republican), Michael H. Schlossberg (Democratic), and Danilo Burgos (Democratic).
What is the current status of HB 1439?
This bill is in committee in the House. Introduced May 12, 2025. It must pass committee before a floor vote.
Where can I track HB 1439?
Track HB 1439 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 1439

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 1439

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →